<p>AD = atopic dermatitis; n = number of subjects in the specified category; FAS = full analysis set; PPS = per-protocol analysis set. <sup>a</sup>: There was one subject that did not receive the second vaccination but did not terminate the study prematurely, i.e. returned for the final visit. <sup>b</sup>: more than one reason per subject possible. <sup>c</sup>: 10 subjects with currently active AD had a SCORAD >30 at screening; 2 of these subjects had a SCORAD >39 and were excluded from PPS as major protocol violations. For the volunteers that were excluded from the PPS but had samples available, immunogenicity results were similar to those of the PPS subjects.</p
<p>In the column “Short-term response SOT” is the number of patients given that had a positive respo...
<p>Ten (10) out of 38 participants that were screened for this study, were randomized to receive eit...
<p>Abbreviations; EM, Erythema multiforme; SCARs, Severe cutaneous adverse drug reactions <sup>a</su...
<p>Of 242 screened volunteers, 120 subjects were assessed eligible for enrollment, allocated to one ...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category; ...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...
<p>FAS = full analysis set; IAS = Immunogenicity Analysis Set, subset used for immunogenicity analys...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...
<p>All vaccinations were administered intramuscularly. ChAd63 AMA1 was administered on day 0 and MVA...
<p>Number of individuals screened, randomized and allocated to the three vaccination groups and with...
†<p>Number of subjects included in PK and PD population (N (%)): 4 (67%). Samples from 2 subjects we...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...
(a) Excludes 19 participants who did not answer the question of vaccination status and were not incl...
<p>CONSORT flow diagram showing subject recruitment and follow up. Subjects were allocated to Groups...
<p>TST: tuberculin skin test; ELISpot: enzyme-linked immunospot. <sup>Δ</sup> In these 17 cases a sk...
<p>In the column “Short-term response SOT” is the number of patients given that had a positive respo...
<p>Ten (10) out of 38 participants that were screened for this study, were randomized to receive eit...
<p>Abbreviations; EM, Erythema multiforme; SCARs, Severe cutaneous adverse drug reactions <sup>a</su...
<p>Of 242 screened volunteers, 120 subjects were assessed eligible for enrollment, allocated to one ...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category; ...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...
<p>FAS = full analysis set; IAS = Immunogenicity Analysis Set, subset used for immunogenicity analys...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...
<p>All vaccinations were administered intramuscularly. ChAd63 AMA1 was administered on day 0 and MVA...
<p>Number of individuals screened, randomized and allocated to the three vaccination groups and with...
†<p>Number of subjects included in PK and PD population (N (%)): 4 (67%). Samples from 2 subjects we...
<p>N = number of subjects in the specified group; n = number of subjects in the specified category (...
(a) Excludes 19 participants who did not answer the question of vaccination status and were not incl...
<p>CONSORT flow diagram showing subject recruitment and follow up. Subjects were allocated to Groups...
<p>TST: tuberculin skin test; ELISpot: enzyme-linked immunospot. <sup>Δ</sup> In these 17 cases a sk...
<p>In the column “Short-term response SOT” is the number of patients given that had a positive respo...
<p>Ten (10) out of 38 participants that were screened for this study, were randomized to receive eit...
<p>Abbreviations; EM, Erythema multiforme; SCARs, Severe cutaneous adverse drug reactions <sup>a</su...